Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Interventions: VK2735 Primary Outcome Measure: Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment Time Frame: 78 weeks Study Details Source VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Beginning in 1963, the Schoenenberger-Monnier research group investigated whether specific compounds circulating in the bloodstream might contribute to the initiation and maintenance of sleep
A: Prioritize products with 98% purity, third-party COAs, enteric coating, and clear labeling from reputable manufacturers
These effects are typically short-lived and resolve quickly
Standardized outcome measurement facilitates assessment of individual patient response and contributes to broader understanding of clinical efficacy
